Aromatase Inhibitors in Postmenopausal Women with Hormone Receptor-Positive Breast Cancer: Profiles of Psychological Symptoms and Quality of Life in Different Patient Clusters
- 29 September 2020
- journal article
- research article
- Published by S. Karger AG in Oncology
- Vol. 99 (2), 84-95
- https://doi.org/10.1159/000509651
Abstract
Background: Aromatase inhibitors (AIs) as adjuvant therapy after breast cancer (BC) surgery have demonstrated to reduce the risk of disease recurrence, to lower the risk of contralateral BC, and to improve survival when compared to tamoxifen in patients with limited-stage hormone receptor-positive (HR+) BC. However, AIs are associated with adverse events that can have a significant impact on patient quality of life (QoL). Aim: This study aimed to identify profiles of psychological symptoms and QoL in HR+ BC patients undergoing AI therapy. Method: Data were collected with questionnaires administered at three time points: AI initiation (t0); 3 months after AI initiation (t1); and 6 months after AI initiation (t2). The FACT-G, FACT-B, and FACT-ES questionnaires were used to assess QoL; psychological symptoms were assessed using the SCL-90-R. Results: 43 women were enrolled in the study (t0), and 37 completed the t1 evaluation and 29 the t2 evaluation. We found (1) a progressive decrease over time in FACT-G and FACT-ES scores, in particular in the Physical, Emotional, and Endocrine subscales, and an increase in the SOM (somatization) subscale of the SCL-90-R; (2) the presence of 4 clusters related to different psychological symptoms and QoL evolution over time; (3) that patients belonging to the cluster characterized by worsening symptoms and QoL during time differed from the others in the Emotional subscale of the FACT-B and in the GSI (Global Score), OCD (obsessive-compulsive), DEP (depression), ANX (anxiety), and SLP (sleep disorders) dimensions of the SCL-90-R and had significantly higher BMI levels; and (4) that 3 items from the SCL-90-R and 2 items from FACT Emotional Well-Being subscale were predictive of the “worst” cluster. Conclusions: Although larger studies are needed to confirm these results, our data open up new ways of investigation into the effects of AIs on QoL in HR+ BC patients.Keywords
This publication has 32 references indexed in Scilit:
- Aromatase inhibitor-induced arthralgia: a reviewAnnals of Oncology, 2013
- Adherence to adjuvant hormonal therapy among breast cancer survivors in clinical practice: a systematic reviewBreast Cancer Research and Treatment, 2012
- Predictors of Aromatase Inhibitor Discontinuation as a Result of Treatment-Emergent Symptoms in Early-Stage Breast CancerJournal of Clinical Oncology, 2012
- Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancerBreast Cancer Research and Treatment, 2010
- Depression and obesity: A meta-analysis of community-based studiesPsychiatry Research, 2010
- Survival and safety of exemestane versus tamoxifen after 2–3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trialThe Lancet, 2007
- Fatigue and menopausal symptoms in women with breast cancer undergoing hormonal cancer treatmentAnnals of Oncology, 2006
- Posttraumatic stress disorder following cancer: A conceptual and empirical reviewClinical Psychology Review, 2002
- Rank-Score Tests in Factorial Designs with Repeated MeasuresJournal of Multivariate Analysis, 1999
- Box-Type Approximations in Nonparametric Factorial DesignsJournal of the American Statistical Association, 1997